Table 5 Detailed information of the top 10 sensitivity drugs in low-risk groups
Drug name | Introduction | Drug target | Drug target pathway |
|---|---|---|---|
AZD7762 | AZD7762 is a checkpoint kinase 1 (Chk 1) inhibitor, which has been reported to sensitize many tumor cells to DNA damage | CHEK1, CHEK2 | Cell cycle |
CEP-701 | CEP‐701 is an inhibitor of tyrosine kinase. Treatment with CCEP-701 modulates various signalling pathways and leads to cell growth arrest and programmed cell death in several tumour types | FLT3, JAK2, NTRK1, NTRK2, NTRK3 | Other, kinases |
Methotrexate | Methotrexate (MTX) is a commonly used antimetabolite, which inhibits folate and DNA synthesis to be effective in the treatment of various malignancies | Antimetabolite | DNA replication |
MS-275 | MS-275, a selective class I inhibitor of histone deacetylase (HDAC), exerts anti-tumor activity in various cancer types, including multiple myeloma (MM) | HDAC1, HDAC3 | Chromatin histone acetylation |
Shikonin | Many studies have demonstrated that shikonin exerts strong anticancer effects on various types of cancer by inhibiting cell proliferation and migration, inducing apoptosis, autophagy, and necroptosis | Not defined | Other |
Gefitinib | Gefitinib is an orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor | EGFR | EGFR signaling |
BIBW2992 | BIBW2992 is an irreversible blocker of the ErbB family, acting at the tyrosine kinases of these proteins. Further investigations for the treatment of many other tumors with BIBW2992, e.g., HNSCC and breast cancer, are ongoing | ERBB2, EGFR | EGFR signaling |
Sunitinib | Sunitinib is a tyrosine kinase inhibitor indicated for the treatment of gastrointestinal stromal tumor, advanced renal cell carcinoma, and pancreatic neuroendocrine tumors | PDGFR, KIT, VEGFR, FLT3, RET, CSF1R | RTK signaling |
S-Trityl-L-cysteine | S-Trityl-L-cysteine (STLC) is a well-recognized lead compound known for its anticancer activity owing to its potent inhibitory effect on human mitotic kinesin Eg5 | KIF11 | Mitosis |
Bortezomib | Bortezomib (BTZ) is the first proteasome inhibitor approved by the Food and Drug Administration. It can bind to the amino acid residues of the 26S proteasome, thereby causing the death of tumor cells | Proteasome | Protein stability and degradation |